501364-82-5

501364-82-5 structure

Name: INO-1001
Chemical Name: N-[3-(4-Morpholinyl)propyl]-5-oxo-6,11-dihydro-5H-indeno[1,2-c]is oquinoline-9-sulfonamide
CAS Number: 501364-82-5
Molecular Formula: C₂₃H₂₅N₃O₄S
Molecular Weight: 439.52700
Catalog: Signaling Pathways Cell Cycle/DNA Damage PARP
Create Date: 2018-10-16 14:30:32
Modify Date: 2024-01-02 09:27:37
INO-1001 is a potent and selective Poly (ADP-ribose) polymerase (PARP) inhibitor with an IC50 of 0.05-1 μM. INO-1001 is a potent enhancer of radiation sensitivity and enhances radiation-induced cell killing by interfering with DNA repair mechanisms, resulting in necrotic cell death[1]. INO-1001 has anti-tumor effects[2].

Name	N-[3-(4-Morpholinyl)propyl]-5-oxo-6,11-dihydro-5H-indeno[1,2-c]is oquinoline-9-sulfonamide
Synonyms	9-[N-(3-[morpholin-4-yl]propyl)-aminosulphonyl]-5,6-dihydro-5-oxo-11H-indeno[1,2-c]isoquinoline inotec indeno[1,2c]isoquinoline 9H-Xanthene,9-[bis(4-methoxyphenyl)methylene] 9-[N-(3-[morpholino-4-yl]propyl)-aminosulphonyl]-5,6-dihydro-5-oxo-11H-indeno-[1,2-c]isoquinoline 9-<Bis-(4-methoxy-phenyl)-methylen>-xanthen

Description	INO-1001 is a potent and selective Poly (ADP-ribose) polymerase (PARP) inhibitor with an IC50 of 0.05-1 μM. INO-1001 is a potent enhancer of radiation sensitivity and enhances radiation-induced cell killing by interfering with DNA repair mechanisms, resulting in necrotic cell death[1]. INO-1001 has anti-tumor effects[2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Epigenetics >> PARP Signaling Pathways >> Cell Cycle/DNA Damage >> PARP
Target	PARP:0.05-1 μM (IC50)
References	[1]. Brock WA, et al. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett. 2004 Mar 18;205(2):155-60. [2]. Mason KA, et al. INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Invest New Drugs. 2008 Feb;26(1):1-5. Epub 2007 Jul 13.

Molecular Formula	C₂₃H₂₅N₃O₄S
Molecular Weight	439.52700
Exact Mass	439.15700
PSA	100.14000
LogP	3.92180

501364-67-6

123-00-2

~54%

501364-82-5

Literature: Inotek Pharmaceutical, Corp. Patent: US2006/19980 A1, 2006 ; Location in patent: Page/Page column 31-33; 54 ;

501364-67-6

~42%

501364-82-5

Literature: INOTEK PHARMACEUTICALS CORPORATION Patent: WO2005/82368 A1, 2005 ; Location in patent: Page/Page column 60; 86-87 ;

5264-21-1

501364-82-5

Literature: Jagtap, Prakash G.; Baloglu, Erkan; Southan, Garry J.; Mabley, Jon G.; Li, Hongshan; Zhou, Jing; Van Duzer, John; Salzman, Andrew L.; Szabo, Csaba Journal of Medicinal Chemistry, 2005 , vol. 48, # 16 p. 5100 - 5103

109722-74-9

501364-82-5

5291-20-3

501364-82-5

Precursor 5
501364-67-6 123-00-2 5264-21-1 109722-74-9
5291-20-3
DownStream 0

501364-82-5	3544-24-9
2113650-04-5	58718-67-5
1431326-61-2	1440964-89-5
1252797-26-4	53025-93-7
1315337-39-3	1315337-40-6